BioVersys AG
Clinical trials sponsored by BioVersys AG, explained in plain language.
A biopharma developing anti-infectives for serious bacterial infections.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug duo takes on deadly brain infection
Disease control Not yet recruitingThis study tests a new two-drug combination (Alpibectir and Ethionamide) added to standard treatment for tuberculosis meningitis, a serious brain infection. About 64 adults newly diagnosed with the condition will receive the drugs to see how well they reach the brain and how safe…
Phase 2 • Sponsor: BioVersys AG • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New weapon against superbug pneumonia and blood infections
Disease control Not yet recruitingThis study tests a new antibiotic combination (BV100 plus other drugs) against hard-to-treat infections like pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. About 120 adults in the hospital will receive either the new combo or the best…
Phase 2 • Sponsor: BioVersys AG • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC